Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency 2Neurotoxicity Syndromes 2Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neoplasms 1Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × glucarpidase × Clear all
NCT00219791 2014-09-11

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

BTG International Inc.

Phase 2 Completed

Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡